Metraipolis › archive › dc_e72e507fbd86

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms — Europe PMC PMID:27892678

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/27892678
DOI
10.22034/apjcp.2016.17.10.4647
License (as archived)
solo-consultazione
Archived
2026-11-10T06:59:35.978Z
SHA-256 of the archived text
efcea761918ee06e22963d15aebbd864a818fdf7c7bcc4a7372f68bbdd43fe64
Stable URL of this page
https://metraipolis.com/documento/dc_e72e507fbd86

How to cite

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms — Europe PMC PMID:27892678 — Europe PMC (en), https://europepmc.org/article/MED/27892678 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e72e507fbd86 (Metraipolis archive dc_e72e507fbd86, sha256 efcea761918ee06e22963d15aebbd864a818fdf7c7bcc4a7372f68bbdd43fe64)
BibTeX
@misc{dce72e507fbd86,
  title = {Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms — Europe PMC PMID:27892678},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/27892678},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e72e507fbd86; sha256 efcea761918ee06e22963d15aebbd864a818fdf7c7bcc4a7372f68bbdd43fe64},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/27892678. Agents can read the archived copy with the MCP tool read_document.